GRIN:CA:CNSX-Grown Rogue International Inc (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.9

Change

0.00 (0.00)%

Market Cap

USD 0.20B

Volume

0.15M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-30 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
GTII:CA Green Thumb Industries Inc

N/A

USD 3.91B
TRUL:CA Trulieve Cannabis Corp

N/A

USD 2.38B
CL:CA Cresco Labs Inc

N/A

USD 0.75B
AYR-A:CA Ayr Wellness Inc

N/A

USD 0.32B
PLTH:CA Planet 13 Holdings Inc

N/A

USD 0.22B
AAWH-U:CA Ascend Wellness Holdings Inc.

N/A

USD 0.20B
IAN:CA iAnthus Capital Holdings Inc

N/A

USD 0.17B
JUSH:CA Jushi Holdings Inc

N/A

USD 0.15B
FFNT:CA 4Front Ventures Corp

N/A

USD 0.10B
MRMD:CA MariMed Inc.

N/A

USD 0.10B

ETFs Containing GRIN:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 136.84% 94% A 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 136.84% 94% A 92% A
Trailing 12 Months  
Capital Gain 291.30% 95% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 291.30% 95% A 97% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 78.54% 92% A 90% A-
Dividend Return 78.54% 92% A 90% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 137.54% 15% F 15% F
Risk Adjusted Return 57.11% 99% N/A 98% N/A
Market Capitalization 0.20B 94% A 99% N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.